Pipeline. Innovative products for unmet patient needs. Learn More Technology Platforms. A fully integrated R&D to commercialization platform
Cell and gene therapy science is highly complex. So too is the regulatory environment surrounding it. With deep experience in GMP-manufacturing of cell-based products, we offer an end-to-end portfolio of services to help develop and commercialise life-changing treatments with the potential to dramatically improve patient outcomes.
Marker Cell Therapy, Inc. operates as a clinical-stage developer of a transformative, non-genetically engineered, and multi-antigen T cell therapy platform. SECTOR Health Care Kuur Therapeutics is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology of a specific subset of cytotoxic T cells, called natural killer T cells (NKT cells) and innovative CAR construct Read a collection of Methods from Cell Systems. Access the full article list Patterns is a new gold open access journal that promotes all types of data science research and outputs, and facilitates sharing and collaboration to solve key scientific problems regardless of their originating domain Our Company. The mission of CELL SCRIPT™ is to provide the best products and technologies for making and using RNA for translation in cells for clinical research and therapeutics.. Current products include kits for in vitro transcription, 5' RNA capping using either a cap analog or capping enzymes, and 3' RNA polyadenylation, as well as all-in-one kits for making capped, poly(A)-tailed mRNA Immune Cell Therapy, Inc. | 16 followers on LinkedIn | Immune Cell Therapy has developed a new DNA-based vaccine for Cancer therapy, with an initial focus on patients with lung or breast cancer
Juno Therapeutics is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute.The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. Aspen Neuroscience leverages stem cell biology and genomics to provide the world's first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson disease. ex vivo genome editing with zfns. Sangamo's cell therapy platform employs ZFN genome editing technology ex vivo (outside the body) to edit human cells for therapeutic use. The cells are collected from the patient (autologous approach) or from a healthy donor (allogeneic approach) and shipped to a cGMP manufacturing facility specialized in the production of cell therapies. Accelerating progress and time to market of biopharmaceuticals with our integrated CDMO and Testing Service Platform. Global HQ in Philadelphia, PA. iPS Cell Therapy. This "pretrial clinical research" allowed the RIKEN research team to test the use of iPS cells for the treatment of wet-type age-related macular degeneration (AMD) on a very small scale, in only a handful of patients. Unfortunately, the study was suspended in 2015 due to safety concerns.
Mana Therapeutics is bringing powerful cell therapies to bear on cancers with an unmet medical need. Focusing on novel ways of educating our endogenous immune cells, we have devised clinical cell immune therapies that can eliminate cancer cells and are both safer and have greater breadth than existing therapies.
Revitalize Cell Therapy, Inc. is a California Domestic Corporation filed on October 25, 2019. The company's filing status is listed as Active and its File Number is C4523568. The Registered Agent on file for this company is Alicia Iglesias and is located at 19486 Lurin Ave, Riverside, CA 92508. Santen Inks $252M License to jCyte Ocular Cell Therapy May 9, 2020-BioWorld Santen inks $252M license to Jcyte ocular cell therapy May 8, 2020 By Michael Fitzhugh Keen to address a rare vision-limiting disorder endured by nearly 1.9 million people globally, ophthalmology specialist Santen Pharmaceutical… Read More > The Berkeley Lights Platform can move you toward cell-based breakthroughs faster than you can imagine. Our platform is a fully integrated, end-to-end solution, comprised of proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. SmartCells Performance Training Solutions are perfect for high impact activities, intense training sessions, and physical therapy rehabilitation.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs. Click on a program below to learn more.
Cell Reserves Inc is a Canadian biopharmaceutical company developing a biomolecular shield for therapeutic molecules. In this way, they can increase the longevity of therapies in the body, thus significantly reducing the risks and costs associated with disease management Cell Fluidics Engineering. Cell Fluidics Engineering . Developing intracellular delivery platform to enable engineering of life-saving therapies. About Us. CellFE Technology. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells. Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It Assignee: Activated Cell Therapy, Inc. Inventor: Peter Van Vlasselaer Separation apparatus and method. Patent number: 5663051 Abstract: Disclosed is an apparatus designed to be used for enriching specific cell types from cell mixtures. The apparatus includes a centrifugable device that includes a constriction defining a lower region and a Osaka and Tokyo, Japan, September 4, 2017 - Takeda Pharmaceutical Company Limited (TSE: 4502) and Noile-Immune Biotech Inc. announced that they have entered into a collaboration to develop next generation chimeric antigen receptor T cell therapy (CAR-T).The next generation CAR-T cell therapy was developed by Professor Koji Tamada at Yamaguchi University and Noile-Immune has exclusive license ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced it is
Gene Therapy Companies . All (67) Companies (67) People (0) Investors (4) Funding Rounds (0) Acquisitions (0) Schools (0) Events (0) Hubs (0) Prev. 1-50 . Next. of 67 results Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research. 5,081 . 8.
With >11 years' experience in genome editing and iPSC technologies, ASC provides ISO:9001 quality, customizable Pre-IND filing R&D services for advancing preclinical assay development and drug screening for cell and gene therapy pipelines and bioprocessing/ bioproduction.
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company committed to improving patient lives in the areas of Urology, Neurology and Orthopedics. Since 2011, Creative Medical Technology Holdings, Inc. (CELZ) and our affiliate company Creative Medical Health, Inc. have focused on regenerative medical solutions for
STEM CELL SUPPLEMENTS. Stem cells are cells with the ability to divide for indefinite periods in culture and to give rise to specialized cells. Stem Cell Supplements are developed based on the merits of stem cells and they are applied for degenerative diseases treatments and to stimulate the formation of all the different tissues of the body: muscle, cartilage, tendon, ligament, bone, blood Pluristem Therapeutics Inc.'s cell therapy products are designed to treat patients by stimulating their bodies' own regenerative mechanisms Juno Therapeutics is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute.The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs.
Postdoctoral Fellow - T-Cell Therapy - Analytical Development, with Genentech, Inc.. Apply Today. CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting. May 14, 2020. New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress